Deutsche Bank is maintaining its Buy rating and its $14 price target on Nektar Therapeutics NKTR based upon the company's in-line Q1 results.
According to Deutsche Bank, “With a steadily growing royalty stream from 9 products, 6 programs in late-stage development (1 proprietary, 5 partnered), and a significant early stage pipeline comprised of 9 candidates, Nektar looks increasingly well positioned to participate in a number of potentially lucrative therapeutic markets in the years to come. Hence, we continue to rate Nektar shares Buy.”
NKTR closed at $9.96 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsDeutsche BankHealth CareLife Sciences Tools & ServicesNektar Therapeutics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in